Independence Blue Cross announces three out of five 2026 Clinical Care Innovation Grants to enhance healthcare access and outcomes through innovative projects by leading health systems.
Despite widespread exposure to breast cancer misinformation that heightened fear in many patients, a survey found it did not lead to increased treatment nonadherence.
A phase 3 trial offers new evidence that an immunotherapy drug may outperform chemotherapy for acral melanoma, a rare subtype long underrepresented in clinical research.
Post-hoc analysis shows potential of biomarkers for identifying pancreatic patients who respond to treatment.
AI transforms how Americans navigate the complex healthcare system, offering timely support and enhancing decision-making for patients and providers alike.
Numerous medical societies and experts have labeled the CDC’s decision as dangerous and confusing.
A new analysis suggests that Medicaid expansion was linked to lower mortality for patients with resectable non-small cell lung cancer, with survival benefits emerging gradually and persisting over time.
In 2024, 91% of patients receiving care through the Ryan White HIV/AIDS Program were virally suppressed, underscoring the program’s role in improving HIV outcomes.
Alexa B. D’Angelo, Ph.D., M.P.H. and Jeremiah Johnson share their predictions for HIV challenges in 2026.
Telehealth transforms mental health care for Medicare patients, replacing in-person visits while increasing overall spending, according to recent research findings.
Experts predict shifts in U.S. healthcare for this year, focusing on affordability, consumer demands, mental health equity and the essential role of doulas.
The oral versions may set records in 2026, and glucagon-like peptide 1 (GLP-1) drugs will pick up even more momentum as medications for cardiovascular risk reduction as well as obesity, predict experts.
New guidelines from the Health Resources and Services Administration (HRSA) aim to reduce cost and access barriers for detecting human papillomavirus, which is preventable.
People taking glucagon-like peptide 1 (GLP-1) drugs were 36% less likely to develop colorectal cancer than those taking aspirin, according to a real-world, head-to-head study.
Transthyretin amyloid cardiomyopathy causes heart failure through protein buildup in heart muscle. Three FDA-approved disease-specific therapies are available, but high costs limit access.
Primary care must ensure that patients have access to the full spectrum of preventive tools, including nutrition services, to reduce chronic conditions and avoid their associated costs.
New research reveals how gastric cancer cells exploit WNT signaling for growth, revealing potential treatment targets to combat this deadly disease.
Universal recommendations dropped include vaccines for COVID-19 and flu shots.
Long-term Medicaid expansion was linked to substantial growth in PrEP prescribing, with earlier expansion states seeing far higher PrEP uptake relative to new HIV diagnoses, according to a recent study.
Write-ups of presentations on the 340B Drug Pricing Program were among the most viewed conference-related articles on the MHE website in 2025.
The most-viewed articles from our print publication included our November 2025 cover story on AI and our April 2025 cover story on Medicaid cuts.
Lytenava, an ophthalmic bevacizumab formulation to treat patients with wet age-related macular degeneration, received yet another FDA complete response letter. The agency is asking for confirmatory efficacy data beyond existing NORSE trial results.
Lucille Accetta, RPh, M.P.H., MBA, of CVS Health, foresees more progress in the push for simplification. A.J. Loiacono of Judi Health and Capital Rx, predicts unified management of healthcare financing and benefits on one "healthcare operating system."
Predictions from Tracy Baroni Allmon, BS Pharm, Eva Borden, Sharon Faust, Mike Kolodij, and James Margiotta
The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients experiencing increased skin cancer risk, highlighting the need for vigilant monitoring and innovative treatment strategies.
Predictions from Marci Chodroff, M.D., Jeffrey Casberg, RPh, M.S., Sarah Emond, M.P.P., Adam Kautzner, Pharm.D., David Fields, Nate Karnitz, MBA, and David Blair
New studies from the year revealed connections between medications, environmental factors and innovative treatments for skin conditions including vitiligo and atopic dermatitis.
GLP-1 obesity drugs saw shifting coverage and access in 2025, with low long-term adherence, payer cost concerns, new generics and key regulatory and formulary moves shaping use.
